DMK Pharmaceuticals Announces Presentation of Preclinical Results Comparing Effects of DPI-125 on Opioid Withdrawal Behaviors Versus Standard of Care for Opioid Use Disorder at SfN Neuroscience 2023
13 Novembre 2023 - 4:52PM
DMK Pharmaceuticals Corporation (NASDAQ: DMK), a commercial stage
neuro-biotech company primarily focused on developing and
commercializing products for the treatment of opioid overdose and
substance use disorders, today announced the presentation of
preclinical results comparing the effects of DPI-125 on opioid
withdrawal behaviors to methadone and buprenorphine, the standard
of care for opioid use disorder (OUD), in a poster session at the
Society for Neuroscience Annual Meeting (SfN Neuroscience 2023)
held November 11-13, 2023 in Washington D.C. DPI-125 is a novel,
small-molecule triple (mu, delta and kappa) opioid receptor
agonist, being developed for the treatment of opioid use disorder.
“Only about 12% of patients receive treatment for
OUD, despite the proven efficacy of current medications.
Buprenorphine, the market leader with US sales in excess of $3B in
2022, requires an induction phase to induce withdrawal symptoms
prior to initiating the first dose. It is challenging for a patient
to voluntarily experience these symptoms. In addition,
buprenorphine can be abused. For this and other reasons, widespread
adoption is low. We believe that DPI-125, our novel clinical stage
compound, will be able to overcome this and several other barriers
to treatment initiation and maintenance. The positive data to be
presented today marks the first step to realizing this promise,”
said Eboo Versi, M.D., Ph.D., CEO of DMK Pharmaceuticals. “We are
excited to present preclinical data comparing DPI-125, a triple
opioid agonist, to the standard of care treatments buprenorphine
and methadone to alleviate withdrawal symptoms. This preclinical
study was financially supported by a grant from the National
Institute of Drug Abuse (NIDA), and we believe that it warrants
further development.”
Details of the poster are as follows:
Title: Effect of DPI-125 on opioid
withdrawal behaviors in rats: a comparison study withmethadone and
buprenorphineProgram Number / Poster Number:
Poster 297.01 / SS14Session Title: G.09. Drugs of
Abuse and AddictionSession Date, Time: Monday,
November 13, 2023, 1:00 p.m. - 5:00 p.m.
ETPresenter: Adam Mar, Ph.D., Assistant Professor,
Department of Neuroscience and Physiology at NYU Grossman School of
MedicineLocation: WCC Halls A-C
The poster will be available on DMK’s website
following the presentation session.
For more details about the Society for Neuroscience
Annual Meeting, please
visit: https://www.sfn.org/meetings/neuroscience-2023
About DMK Pharmaceuticals
DMK Pharmaceuticals is a commercial stage
neuro-biotech company primarily focused on developing and
commercializing products for the treatment of opioid overdose and
substance use disorders. DMK’s commercial products approved by the
FDA include ZIMHI® (naloxone) Injection for the treatment of opioid
overdose, and SYMJEPI® (epinephrine) Injection for use in the
emergency treatment of acute allergic reactions, including
anaphylaxis. The Company is focused on developing novel therapies
for opioid use disorder (OUD) and other important neuro-based
conditions where patients are currently underserved. DMK believes
its technologies are at the forefront of endorphin-inspired drug
design with its mono, bi- and tri-functional small molecules that
simultaneously modulate critical networks in the nervous system.
DMK has a library of approximately 750 small molecule neuropeptide
analogues and a differentiated pipeline that could address unmet
medical needs by taking the novel approach to integrate with the
body’s own efforts to regain balance of disrupted physiology. The
Company’s lead clinical stage product candidate, DPI-125, is being
studied as a potential novel treatment for OUD. DMK also plans to
develop the compound for the treatment of moderate to severe pain.
The Company’s other development stage product candidates include
DPI-221 for bladder control problems and DPI-289 for severe end
stage Parkinson’s disease. For additional information about DMK
Pharmaceuticals, please visit our website and follow us on Twitter
and LinkedIn.
Forward Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are identified by
terminology such as “may,” “should,” “expects,” “plans,”
“anticipates,” “could,” “intends,” “target,” “projects,”
“contemplates,” “believes,” “estimates,” “predicts,” “potential” or
“continue” or the negative of these terms or other similar words.
Such forward-looking statements include those that express plans,
anticipation, intent, contingencies, goals, targets or future
development and/or otherwise are not statements of historical fact.
These statements relate to anticipated future events or future
results of operations, including, but not limited to, statements
concerning (i) the ability of the Company to raise additional funds
required to sustain the Company’s ongoing operations and fund the
anticipated development activities regarding DPI-125, (ii) whether,
if successfully developed, DPI-125 will receive a more favorable
drug scheduling or be a more patient friendly treatment, (iii) the
potential benefits of DPI-125 if successfully developed, and (iv)
our ability to increase sales of our commercial products. These
statements are only predictions and involve known and unknown
risks, uncertainties, and other factors, which may cause Adamis’
actual results to be materially different from the results
anticipated by such forward-looking statements. These statements
also assume that the Company will have or be able to obtain
sufficient funding to support the activities described in this
press release, continue the Company’s operations and satisfy the
Company’s liabilities and obligations in a timely manner. There can
be no assurance that this will be the case. Also, such statements
assume that there are no significant unexpected developments or
events that delay or prevent such activities from occurring. The
Company will require additional funds to sustain operations,
satisfy our obligations and liabilities, and fund its ongoing
operations. There are no assurances that required funding will be
available at all or will be available in sufficient
amounts. Failure to timely obtain any required additional
funding, or unexpected developments or events, could delay the
occurrence of such events or prevent the events described in any
such statements from occurring which could adversely affect our
business, financial condition and results of operations. If we
cannot continue as a viable entity, we might be required to reduce
or cease operations or seek dissolution and liquidation or
bankruptcy protection, and our stockholders would likely lose most
or all of their investment in us. Accordingly, you should not rely
upon forward-looking statements as predictions of future events.
Adamis cannot assure you that the events and circumstances
reflected in the forward-looking statements will be achieved or
occur, and actual results could differ materially from those
projected in the forward-looking statements. You should not place
undue reliance on any forward-looking statements. Further, any
forward-looking statement speaks only as of the date on which it is
made, and except as may be required by applicable law, we undertake
no obligation to update or release publicly the results of any
revisions to these forward-looking statements or to reflect events
or circumstances arising after the date of this press release.
Certain of these risks and additional risks, uncertainties, and
other factors are described in greater detail in Adamis’ filings
from time to time with the SEC, including its annual report on Form
10-K for the year ended December 31, 2022, and subsequent filings
with the SEC, which Adamis strongly urges you to read and consider,
all of which are available free of charge on the SEC’s website at
http://www.sec.gov.
Investor and Media Contact:Maria
YonkoskiICR Westwicke203-682-7167
Grafico Azioni DMK Pharmaceuticals (NASDAQ:DMK)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni DMK Pharmaceuticals (NASDAQ:DMK)
Storico
Da Giu 2023 a Giu 2024